WO2000076537A3 - Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases - Google Patents

Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases Download PDF

Info

Publication number
WO2000076537A3
WO2000076537A3 PCT/US2000/011008 US0011008W WO0076537A3 WO 2000076537 A3 WO2000076537 A3 WO 2000076537A3 US 0011008 W US0011008 W US 0011008W WO 0076537 A3 WO0076537 A3 WO 0076537A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
virus
semi
aids
treatment
Prior art date
Application number
PCT/US2000/011008
Other languages
French (fr)
Other versions
WO2000076537A2 (en
Inventor
Sebastiano Gattoni-Celli
Gene Shearer
Edith Grene
Danforth A Newton
Edwin A Brown
Jay A Berzofsky
Anne S Degroot
Original Assignee
Us Health
Univ South Carolina
Gattoni Celli Sebastiano
Gene Shearer
Edith Grene
Danforth A Newton
Edwin A Brown
Jay A Berzofsky
Anne S Degroot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/015920 external-priority patent/WO1998011202A1/en
Application filed by Us Health, Univ South Carolina, Gattoni Celli Sebastiano, Gene Shearer, Edith Grene, Danforth A Newton, Edwin A Brown, Jay A Berzofsky, Anne S Degroot filed Critical Us Health
Priority to AU48016/00A priority Critical patent/AU4801600A/en
Publication of WO2000076537A2 publication Critical patent/WO2000076537A2/en
Publication of WO2000076537A3 publication Critical patent/WO2000076537A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Abstract

The present invention provides a composition comprising a semi-allogeneic hybrid fusion cell and an immunogenic peptide. In particular, isolated peptides of HIV (Human Immunodeficiency Virus), HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus are provided in the compositions of the present invention. Moreover, isolated cancer-specific peptides specific to a cancer, for example, B cell lymphoma, T cell lymphoma, myeloma, leukemia, breast cancer, pancreatic cancer, colon cancer, lung cancer, renal cancer, liver cancer, prostate cancer, melanoma and cervical cancer are provided in the compositions of the present invention.
PCT/US2000/011008 1997-09-10 2000-04-24 Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases WO2000076537A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48016/00A AU4801600A (en) 1999-06-16 2000-04-24 Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1997/015920 WO1998011202A1 (en) 1996-09-10 1997-09-10 Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids
US25455699A 1999-06-16 1999-06-16
US09/254,556 1999-06-16

Publications (2)

Publication Number Publication Date
WO2000076537A2 WO2000076537A2 (en) 2000-12-21
WO2000076537A3 true WO2000076537A3 (en) 2001-05-03

Family

ID=26792754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011008 WO2000076537A2 (en) 1997-09-10 2000-04-24 Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases

Country Status (1)

Country Link
WO (1) WO2000076537A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (en) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogeneic anti-tumor vaccine with HLA-haplo-identical antigen-presenting cells
CA2743669C (en) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273716A2 (en) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
WO1993019775A1 (en) * 1992-03-31 1993-10-14 Medimmune, Inc. Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins
WO1998011202A1 (en) * 1996-09-10 1998-03-19 Medical University Of South Carolina Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids
WO1998033527A2 (en) * 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273716A2 (en) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
WO1993019775A1 (en) * 1992-03-31 1993-10-14 Medimmune, Inc. Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins
WO1998011202A1 (en) * 1996-09-10 1998-03-19 Medical University Of South Carolina Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids
WO1998033527A2 (en) * 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRENE E. ET AL.: "Alloimunization for immune based therapy in AIDS malignancies", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES., vol. 21, 1 May 1999 (1999-05-01), NEW YORK US, pages a16, XP000974801 *
HOSMALIN A. ET AL.: "Priming with T helper cell epitopes enhances the antibody response to the envelope glycoprotein of HIV-1 in primates", JOURNAL OF IMMUNOLOGY., vol. 146, 1991, BALTIMORE US, pages 1667 - 1673, XP000971372, ISSN: 0022-1767 *
NEWTON D.A. ET AL.: "Semiallogeneic cell hybrids as therapeutic vaccines for cancer", JOURNAL OF IMMUNOTHERAPY., vol. 23, March 2000 (2000-03-01), NEW YORK US, pages 246 - 254, XP000971375, ISSN: 1053-8550 *
SHEARER G M ET AL: "Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS", IMMUNOLOGY TODAY, vol. 20, no. 2, February 1999 (1999-02-01), CAMBRIDGE GB, pages 66 - 71, XP004157278, ISSN: 0167-5699 *

Also Published As

Publication number Publication date
WO2000076537A2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
EP1461079B8 (en) Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
AU5376201A (en) Methods and compositions for impairing multiplication of hiv-1
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
DE69531204D1 (en) FACTOR IX FORMULATIONS
WO1999033868A3 (en) Human papillomavirus vaccine
CZ63995A3 (en) Virus vectors and their use in gene therapy
ES2150595T3 (en) PREPARATION PROCEDURE OF A VIRAL VECTOR OF AT LEAST 20 KB BY INTERMOLECULAR HOMOLOGICAL RECOMBINATION IN A PROCARIOT CELL.
IL202249A (en) Nucleic acids encoding modified human immunodeficiency virus type 1 (hiv-1) group m consensus envelope glycoproteins
IL123514A0 (en) Antagonists of the oncogenic activity of the protein MDM2 and use thereof in the treatment of cancers
WO2001045712A8 (en) Combinations of medicaments for treating viral diseases
NZ518999A (en) Vaccine compositions
AU3814799A (en) Chiral phosphorated ligands useful in catalysts
PL324289A1 (en) Encapsulated cells producing virus particles
GB2355983B (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
WO2000076537A3 (en) Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
CA2340888A1 (en) Novel tumor antigen protein sart-3 and tumor antigen peptide thereof
IL139604A0 (en) Novel peptides
AU6078399A (en) Ligand presenting assembly (lpa), method of preparation and uses thereof
CA2095335A1 (en) Cell growth inhibitors
MXPA04002530A (en) Therapeutically useful triethyleneglycol cholesteryl oligonucleotides.
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
WO2004108886A3 (en) Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1999 254556

Date of ref document: 19990616

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP